1. Home
  2. OPRT vs AGEN Comparison

OPRT vs AGEN Comparison

Compare OPRT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oportun Financial Corporation

OPRT

Oportun Financial Corporation

N/A

Current Price

$8.10

Market Cap

275.7M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$7.13

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRT
AGEN
Founded
2005
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.7M
274.8M
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
OPRT
AGEN
Price
$8.10
$7.13
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$7.00
$14.50
AVG Volume (30 Days)
301.5K
977.6K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
127.18
100.00
EPS
0.22
0.96
Revenue
$956,685,000.00
$42,877,086.00
Revenue This Year
$32.79
$107.63
Revenue Next Year
$4.47
N/A
P/E Ratio
$35.77
$7.23
Revenue Growth
N/A
89.95
52 Week Low
$4.03
$2.71
52 Week High
$8.30
$8.85

Technical Indicators

Market Signals
Indicator
OPRT
AGEN
Relative Strength Index (RSI) 62.29 45.94
Support Level $7.12 $2.97
Resistance Level $8.30 $8.64
Average True Range (ATR) 0.28 0.47
MACD -0.01 -0.21
Stochastic Oscillator 76.85 16.67

Price Performance

Historical Comparison
OPRT
AGEN

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: